back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2024-03-28 21:02 Tx date 2024-03-28 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Warrants
15 - Acquisition or disposition under a prospectus
|
$15,000
+5,000 vol $3.00 each |
5,000 | |
| Filed 2024-03-28 21:01 Tx date 2020-10-26 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2024-03-28 21:00 Tx date 2024-03-28 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Common Shares
15 - Acquisition or disposition under a prospectus
|
$23,500
+10,000 vol $2.35 each |
10,000 | |
| Filed 2024-03-28 20:59 Tx date 2020-10-26 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2023-05-24 11:12 Tx date 2023-05-23 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$80,500
+50,000 vol $1.61 each |
375,000 | |
| Filed 2023-02-24 21:15 Tx date 2023-02-22 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$48,500
+25,000 vol $1.94 each |
325,000 | |
| Filed 2022-11-17 17:03 Tx date 2022-11-15 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$87,000
+50,000 vol $1.74 each |
300,000 | |
| Filed 2022-04-18 12:48 Tx date 2022-04-12 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$110,000
+50,000 vol $2.20 each |
250,000 | |
| Filed 2022-03-16 13:26 Tx date 2021-01-04 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$111,500
+50,000 vol $2.23 each |
150,000 | |
| Filed 2021-09-14 20:08 Tx date 2021-09-13 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$105,000
+50,000 vol $2.10 each |
150,000 | |
| Filed 2020-11-02 11:41 Tx date 2020-10-26 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$176,000
+100,000 vol $1.76 each |
100,000 | |
| Filed 2020-11-02 11:38 Tx date 2020-10-26 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-10-29 18:09 Tx date 2020-10-26 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-10-29 18:09 Tx date 2020-10-26 |
$NGEN
NervGen Pharma Corp. |
Kaye, Randall
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
100,000 |